What this band has actually done:
stocks scoring 25–45
beat the S&P 500 over the next three months
45.3%
of the time, across 39,662 cases
since 2015.
That is below a coin flip — and so is every other band, because the
median stock loses to a cap-weighted index.
How we measured this
Hedge funds
44
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$8.8B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqCM
About TG THERAPEUTICS INC
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the…
Who's behind the signal
Every informed buyer we can see on TGTX, across all three feeds.
No significant Form 4 insider activity in the window.
Congressional trades · 1 on record
Disclosures from 2020-09-08 to 2020-09-08
The newest disclosure we hold for this stock is 2020-09-08.
That is the end of our data, not necessarily the end of the trading — our
bulk STOCK Act archive stops there and newer filings arrive through a
separate live feed. Treat the absence of recent rows as “not covered”,
not as “no trades”.
Not a model pick — but on our radar.
TG THERAPEUTICS INC isn't in the top-10 model right now, but 9 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
9
Investors
2
New positions
5
Increasing
1
Decreasing
1
Unchanged
Price History
Loading price data...
▲
A member of Congress bought
▼
A member sold
Return: High: Low:
Markers sit on the transaction date the member disclosed, snapped to the
nearest close on the chart. They are not the date the public found out — that
came later, and
the gap is its own page.
Every marker is listed by name in the table above.
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
How much of each investor's portfolio is allocated to TG THERAPEUTICS INC
Insider Trading (Form 4)
Recent trades by company officers and directors — filed within 2 days of each trade
Neutral
Sentiment
0
Buys
1
Sells
Date
Insider
Title
Action
Shares
Price
Value
2026-09-10
Charney Laurence N
Insider
SELL
5,000
$54.96
$274,800
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell TG THERAPEUTICS INC or any security.